Aleix Prat: Our DNADX plasma-based assay in 160 patients with metastatic breast cancer
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a post on LinkedIn:
“Check our DNADX plasma-based assay in 160 patients with metastatic breast cancer treated with trastuzumab deruxtecan or sacituzumab govitecan.
DNADX subtypes are highly prognostic.
DNADX signatures predict ER status, and brain disease.
Led by Paolo Tarantino Dana-Farber Cancer Institute Reveal Genomics, S.L.”
More posts featuring Aleix Prat.
Aleix Prat is the Director of the Cancer Institute at the Hospital Clinic of Barcelona, Head of the Translational Genomics Group at IDIBAPS, and a Professor at the University of Barcelona.
He is also a Co-Founder of REVEAL GENOMICS, S.L. His work focuses on breast cancer genomics and the development of omics-based assays for clinical application. His expertise lies in breast cancer and gene expression profiling.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023